Biohaven Reports Third-Quarter 2026 Results and FDA Acceptance of Vyglxia Resubmission
The FDA accepted Biohaven’s resubmitted new drug application for Vyglxia. The body is truncated and provides no financial results details.
Related stories
Q2 Results Live Updates: Suzlon, Trent react to numbers; RIL, Sun Pharma, BEL, report today
Q2 Results Live Updates: The final trading day of the week will bring in a plethora of result reactions and plenty of earnings as well from Nifty 50 and broader market companies. R
H impact | EQUITY | Oct 30, 2026, 03:06 AM UTC
BOJ to Sell ETF Holdings at About 0.1% of Market Trading Value
M impact | EQUITY | Oct 30, 2026, 03:03 AM UTC
Nikkei Futures Down 2.6% After BOJ Decision
Nikkei futures were last down 2.6%, largely unmoved by the BOJ decision.
M impact | EQUITY | Oct 30, 2026, 03:03 AM UTC
Asian session market picture: S&P 500 -0.99%, Nasdaq 100 -2.2%; USD/JPY -0.12%, WTI +1.28%, 1810 leads volume
Asian session market picture. US index futures: S and P futures is down 0.99 percent, Nasdaq futures is down 2.2 percent, Dow futures is down 0.16 percent and Russell futures is do
M impact | EQUITY | Oct 30, 2026, 03:00 AM UTC
Sarimelati Kencana Attributes Q3 2026 Net Profit Growth to Operating Efficiencies
M impact | EQUITY | Oct 30, 2026, 02:58 AM UTC
South Korea's Kospi Extends Losses, Down 5.3% at 5,622.84
M impact | EQUITY | Oct 30, 2026, 02:57 AM UTC